CMMB net incomeFY2025-$8.99M
CMMB net income was -$8.99M for fiscal 2025 (ended Dec 31, 2025), compared with -$13.95M in fiscal 2024.
Chemomab Therapeutics Ltd. (CMMB) financials
For fiscal 2025 (ended Dec 31, 2025), Chemomab Therapeutics Ltd. reported -$8.99M of net income.
- Net income, FY2025
- -$8.99M
- Free cash flow, FY2025
- -$11.13M
- EPS, diluted, FY2025
- $0.02
- Cash
- $7.56M
- Market cap
- $10.5M
FY2016FY2025
FY2016FY2025
CMMB revenue and earnings growth
CMMB EPSFY2025$0.02
CMMB diluted EPS was $0.02 for fiscal 2025 (ended Dec 31, 2025).
CMMB free cash flowFY2025-$11.13M
CMMB free cash flow was -$11.13M for fiscal 2025 (ended Dec 31, 2025), compared with -$15.39M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | $2.33M | $2.46M | $4.39M | $5.14M | $3.31M | - | - | - | - | - |
| Research and development | $5.83M | $11.33M | $18.38M | $16.98M | $6.33M | $4.68M | $13.30M | $7.51M | $6.23M | $2.38M |
| Selling, general and admin | $3.73M | $3.41M | $7.08M | $11.56M | $6.03M | $1.29M | $6.25M | $5.52M | $3.16M | $2.26M |
| Operating income | -$112.00M | -$103.00M | - | - | - | - | - | -$13.04M | -$9.39M | -$4.64M |
| Interest expense | - | - | - | - | - | - | - | $741.0K | $92.0K | $7.0K |
| Pre-tax income | -$8.99M | -$13.95M | -$24.22M | -$28.18M | -$12.48M | $5.95M | $27.12M | $13.49M | -$9.48M | -$4.61M |
| Income tax | $0 | $0 | $0 | -$534.0K | $0 | $0 | $0 | $306.0K | $323.0K | $137.0K |
| Net income | -$8.99M | -$13.95M | -$24.22M | -$27.65M | -$12.48M | -$5.95M | -$27.12M | -$13.80M | -$9.81M | -$4.74M |
| EPS, basic | $0.02 | $0.04 | $0.10 | $0.12 | $0.06 | $0.04 | $0.79 | $1.09 | - | - |
| EPS, diluted | $0.02 | $0.04 | $0.10 | $0.12 | $0.06 | $0.04 | $0.79 | $1.09 | - | - |
| Diluted shares | 510.2M | 359.0M | 235.0M | 227.6M | 207.5M | 136.8M | 34,446 | 12.6M | 9.0M | 5.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.56M | $6.07M | $9.37M | $13.60M | $15.24M | $11.73M | $12.28M | $7.64M | $1.45M | $4.56M |
| Receivables | - | - | - | - | - | - | $408.0K | $3.40M | $400.0K | - |
| Current assets | $13.43M | $16.04M | $20.90M | $41.74M | $62.69M | $11.84M | $18.21M | $10.92M | $1.85M | - |
| Total assets | $13.81M | $16.96M | $22.15M | $43.06M | $64.35M | $12.48M | $19.75M | $12.76M | $2.09M | - |
| Current liabilities | $1.48M | $3.22M | $4.84M | $6.75M | $2.65M | $1.32M | $4.12M | $2.75M | $2.70M | - |
| Total liabilities | $1.48M | $3.43M | $5.15M | $6.84M | $2.89M | $1.67M | $4.85M | $2.96M | $2.70M | - |
| Shareholders' equity | $12.33M | $13.54M | $17.00M | $36.22M | $61.47M | $10.80M | $12.37M | $9.80M | -$609.0K | $3.30M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.13M | -$15.39M | -$23.61M | -$20.37M | -$12.37M | -$5.24M | -$16.46M | -$14.22M | -$8.52M | -$3.73M |
| Capital expenditures | $3.0K | $0 | $3.0K | $68.0K | $239.0K | $38.0K | $95.0K | $213.0K | $34.0K | $75.0K |
| Free cash flow | -$11.13M | -$15.39M | -$23.61M | -$20.44M | -$12.61M | -$5.28M | -$16.55M | -$14.44M | -$8.55M | -$3.81M |
| Investing cash flow | $5.39M | $2.30M | $15.88M | $19.53M | -$45.19M | -$62.0K | -$95.0K | -$213.0K | -$34.0K | $78.0K |
| Financing cash flow | $7.16M | $9.87M | $3.50M | -$808.0K | $61.07M | $4.75M | $26.62M | $20.62M | $5.24M | $6.06M |
| Stock-based compensation | $623.0K | $617.0K | $1.49M | $3.21M | $2.02M | $130.0K | $1.16M | $1.93M | $730.0K | $270.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS growth, YoY | - | - | -14.9% | 101.7% | - | - | - | - | - | - |
| Return on equity | -72.9% | -103.0% | -142.5% | -76.3% | -20.3% | -55.1% | -219.2% | -140.7% | - | -143.9% |
| Return on assets | -65.1% | -82.2% | -109.3% | -64.2% | -19.4% | -47.7% | -137.3% | -108.1% | -469.9% | - |
| Current ratio | 9.08 | 4.98 | 4.32 | 6.18 | 23.66 | 9.00 | 4.42 | 3.98 | 0.69 | - |
Income statement
| Line item | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $6.89M | $5.89M | $5.42M | $2.91M | $2.75M | $2.38M | $1.49M | $1.31M | $1.16M | $1.25M | $1.03M | $847.0K |
| Selling, general and admin | $2.16M | $2.75M | $2.89M | $3.34M | $2.58M | $2.64M | $1.40M | $1.45M | $542.0K | $688.0K | $194.0K | $254.0K |
| Pre-tax income | -$8.73M | -$8.26M | -$8.08M | -$6.73M | -$5.10M | -$5.04M | -$2.97M | -$2.77M | -$1.70M | - | - | - |
| Income tax | $21.0K | $10.0K | $0 | -$544.0K | $0 | $0 | $0 | $0 | $0 | - | - | - |
| Net income | -$8.75M | -$8.27M | -$8.08M | -$6.19M | -$5.10M | -$5.04M | -$2.97M | -$2.77M | -$1.70M | -$1.95M | -$1.22M | -$1.08M |
| EPS, basic | $0.04 | $0.04 | $0.04 | $0.03 | $0.02 | - | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 |
| EPS, diluted | $0.04 | $0.04 | $0.04 | $0.03 | $0.02 | - | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 | $0.01 |
| Diluted shares | 221.0M | - | 228.8M | 228.2M | 228.1M | - | 228.0M | 216.3M | 156.8M | - | 139.4M | 129.8M |
Balance sheet
| Line item | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.77M | $13.60M | $10.74M | $9.88M | $13.91M | $15.24M | $37.80M | $45.45M | $58.23M | $11.73M | $12.73M | $13.08M |
| Current assets | $33.78M | $41.74M | $48.73M | $54.83M | $59.34M | $62.69M | $65.84M | $68.83M | $59.52M | $11.84M | $7.39M | $9.67M |
| Total assets | $35.01M | $43.06M | $50.22M | $56.38M | $60.96M | $64.35M | $67.44M | $70.52M | $60.12M | $12.48M | $7.69M | $10.02M |
| Current liabilities | $7.00M | $6.75M | $5.48M | $4.39M | $3.52M | $2.65M | $1.63M | $2.16M | $4.63M | $1.32M | $2.27M | $1.75M |
| Total liabilities | $7.06M | $6.84M | $5.59M | $4.54M | $3.72M | $2.89M | $1.93M | $2.48M | $4.96M | $1.67M | $2.34M | $1.86M |
| Shareholders' equity | $27.95M | $36.22M | $44.62M | $51.84M | $57.24M | $61.47M | $65.51M | $68.04M | $55.16M | $10.80M | $12.16M | $12.80M |
Cash flow
| Line item | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.19M | -$5.70M | -$5.25M | -$5.70M | -$3.71M | -$2.89M | -$2.58M | -$5.61M | -$1.29M | -$1.55M | -$901.0K | -$873.0K |
| Capital expenditures | $1.0K | $1.0K | $42.0K | $11.0K | $14.0K | $134.0K | $0 | $102.0K | $3.0K | $1.0K | $20.0K | $7.0K |
| Free cash flow | -$7.19M | -$5.70M | -$5.30M | -$5.71M | -$3.73M | -$3.03M | -$2.58M | -$5.71M | -$1.30M | -$1.56M | -$921.0K | -$880.0K |
| Investing cash flow | $14.43M | $9.35M | $6.07M | $1.73M | $2.38M | -$19.58M | -$5.00M | -$20.60M | -$2.0K | -$3.0K | -$20.0K | -$29.0K |
| Financing cash flow | $0 | -$869.0K | $39.0K | $22.0K | $0 | -$81.0K | -$72.0K | $13.43M | $47.80M | $563.0K | $562.0K | $3.13M |
| Stock-based compensation | $484.0K | $740.0K | $836.0K | $761.0K | $874.0K | $1.01M | $441.0K | $527.0K | $43.0K | $33.0K | $23.0K | $28.0K |
Key ratios
| Line item | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS growth, YoY | 81.8% | - | 169.2% | 107.7% | - | - | - | - | -15.4% | - | - | - |
| Current ratio | 4.83 | 6.18 | 8.90 | 12.48 | 16.87 | 23.66 | 40.39 | 31.88 | 12.85 | 9.00 | 3.25 | 5.52 |
Source: XBRL data Chemomab Therapeutics Ltd. files with the SEC, latest filing dated Mar 23, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CMMB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CMMB | - | - | -$8.99M | - | $10.5M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
CMMB FAQ
6 questionsIs CMMB profitable?
No. Chemomab Therapeutics Ltd. reported a net loss of $8.99M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does CMMB have?
Chemomab Therapeutics Ltd. reported $7.56M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CMMB free cash flow?
Chemomab Therapeutics Ltd. generated -$11.13M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$11.13M less capital expenditures.What is CMMB earnings per share?
Diluted earnings per share were $0.02 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did CMMB last report financial results?
The latest statements here come from Chemomab Therapeutics Ltd.'s 20-F filed on Mar 23, 2026, covering the period ended Dec 31, 2025.Where does this CMMB financial data come from?
Quantisnow builds these statements from the structured XBRL data Chemomab Therapeutics Ltd. files with the SEC. It is provided for information only and is not investment advice.